Onyx Expects Suitors to Include Amgen, Pfizer

Cancer-drug developer Onyx Pharmaceuticals is expecting takeover interest from roughly five companies, including Amgen and Pfizer, in an acquisition that could be valued at more than $10 billion.

Speak Your Mind

Subscribe to get this amazing EBOOK FREE

Real Estate 101 - Buying Your First Home!

By subscribing to this newsletter you agree to our Privacy Policy